# Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

> **NCT02194751** · PHASE2 · NOT_YET_RECRUITING · sponsor: **XEME Biopharma Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Oncoquest-L vaccine

## Key facts

- **NCT ID:** NCT02194751
- **Lead sponsor:** XEME Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-07
- **Primary completion:** 2024-06
- **Final completion:** 2026-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194751, "Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02194751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*